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Abstract
Background: After platinum and taxane chemotherapy, with or without bevacizumab, active regimens for
advanced or recurrent cervical cancer are lacking. Our objective was to review a single institution experience in
treating recurrent, refractory cervical cancer with nano-particle albumin bound (NAB) paclitaxel with or without
bevacizumab.
Methods: This retrospective case series was conducted in accordance with the regulations set forth by the
Institutional Review Board at St. Joseph’s Hospital and Medical center. The chemotherapy log at the outpatient
infusion center at the University of Arizona Cancer Center was reviewed to identify all advanced cervical cancer
patients treated with NAB-paclitaxel from November 2011 until February 2015. The following data points were
extracted from patient charts: demographic information, number of cycles, progression free survival (PFS), overall
survival (OS), dose reductions and dose-limiting toxicities. In addition the average number of treatment cycles and
age at recurrence were calculated.
Results: A total of 12 subjects were identified as receiving treatment with NAB-paclitaxel. Mean age at time of
recurrence was 47.2 years (36–55). Nine subjects had squamous cell histology and three subjects had adenocarcinoma
histology. All subjects had failed treatment with platinum and taxane, or platinum and topotecan chemotherapy.
Two subjects were lost to follow up. The Median number of cycles of NAB-paclitaxel was 6.5 (2–19). The total
number of cycles of NAB-paclitaxel in the study population was 65. Seven subjects were treated in combination
with bevacizumab. Of these, three subjects are still alive and one subject is currently receiving active treatment
with NAB-paclitaxel. The median PFS and OS for all subjects that met mortality endpoint was 4.8 months and
8.9 months (n = 7), respectively. One subject discontinued NAB-paclitaxel secondary to peripheral neuropathy, and one
subject developed a vesicovaginal fistula while obtaining combination NAB-paclitaxel and bevacizumab therapy.
Conclusions: NAB-paclitaxel with or without bevacizumab is tolerable and potentially active in treating recurrent
cervical cancer after failing platinum-taxane or topotecan chemotherapy. This small case series deserves confirmation
through prospective clinical trials.
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Background
Hallmarks of recurrent cervical cancer continue to be
poor prognosis, and limited treatment options. In this
heavily pre-treated population with prior radiation, where
disease is not amenable to surgical excision, there has
been an evolution in cytotoxic chemotherapy regimens
[1]. Gynecologic Oncology Group (GOG) protocol 204
established double therapy of cisplatin and paclitaxel as
the standard of care. This combination had an overall re-
sponse rate of 29.1 % [2]. Then, GOG-240 demonstrated
an improvement in both PFS, and OS endpoints from this
doublet with the addition of bevacizumab. By harnessing
this anti-angiogenic agent, there was an addition of
3.4 months to OS [3]. However, if a GOG-240 treatment
regimen fails, there are no established treatment options
in recurrent cervical cancer.
Nano-particle albumin bound (NAB) paclitaxel is a
130-nanimeter, chremophor-free preparation of paclitaxel.
This preparation eliminates the need for pre-medication,
has a shorten infusion time, and increase tumor concen-
tration as compared to standard preparation [4, 5].
NAB-paclitaxel was evaluated in recurrent cervical
cancer a phase II trial as a part of the GOG-127 queue.
For this trial all 35 subjects were taxane naïve. Subjects
were treated with 125 mg/m2 on days 1, 8 and 15 of a
28-day cycle. Results demonstrated moderate activity with
a median PFS, and OS was 5.0 and 9.4 months, respect-
ively. Ten subjects had a partial response, and additional
15 subjects had stable disease [6].
Targeting angiogenesis, the phenotypic driver of cer-
vical cancer, is central to effective therapy of this disease
[7]. In addition to agents that directly inhibit vascular
growth pathways, there is significant data corroborating
that the administration of chemotherapy in reduced doses
with a more frequent schedule produces an anti-angiogenic
effect. So-called metronomic chemotherapy reduces endo-
thelial repair time, endothelial cell proliferation, migration
and circulating levels of endothelial progenitor cells [8–10].
Thus, based on a prior positive phase II evaluation of
NAB-paclitaxel, and anti-angiogenic induced properties
with metronomic administration we treated recurrent
cervical cancer patient that failed prior chemotherapy
with NAB-paclitaxel with or without bevacizumab.
Methods
Patients
This retrospective chart review was conducted in accord-
ance with the regulations set forth by the Institutional Re-
view Board of The Dignity Health at St. Joseph’s Hospital
and Medical Center. The pharmacy chemotherapy log was
review at the University of Arizona Cancer Center
Chemotherapy Infusion Suite at Dignity Health at St.
Joseph’s Hospital and Medical Center from to identify all
patients that received nab-paclitaxel. Charts were review
for patients that had the diagnoses of cervical carcinoma.
All subjects were assigned a subject number, and informa-
tion was de-identified during data collection. The data
points collected included: demographic, tumor history,
prior therapies, adverse events and treatment response.
Statistical considerations
The primary endpoint of this series was PFS defined as
initiation of nab-paclitaxel to discontinuation of treat-
ment. Secondary endpoint included: dose reductions,
completed cycles, adverse events, time to progression,
time to death and indication for discontinuation of therapy.
Adverse events were categorized using the Common Ter-
minology Criteria for Adverse Events (CTCAE – version
4.0) [11]. The median number of cycles, PFS and OS were
calculated.
Results
From November 2011 to February of 2015 time period,
12 patients with the diagnoses of recurrent cervical car-
cinoma received NAB-paclitaxel. Two subjects were
lost to follow up; one patient relocated out-of-state.
The remaining 10 patients had the average age of 43.5
(range 36–55). Seven subjects were self-identified as
non-Hispanic white, 4 subjects Hispanic and one other.
Table 1 displays the demographic characteristic of the
study group.
Table 1 Patient demographics
Characteristic Category n








Cell Type Squamous Cell Carcinoma 7
Adenocarcinoma 3
Lines of Prior Therapy 1 8
2 2
Prior Radiation Yes 9
No 1
Prior Surgery Yes 5
No 5
Prior Paclitaxel Yes 9
No 1
Prior Bevacizumab Yes 6
No 4
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All subjects had recurrent cervical cancer. Of note, prior
to NAB-paclitaxel therapy all subjects had failed prior
cytotoxic chemotherapy. Two subjects failed 2 prior lines
of chemotherapy. Chemotherapy administered in conjunc-
tion with primary radiation, as a radio-sensitizer, was not
counted as a systemic chemotherapy regimen. Nine sub-
jects had prior radiation therapy. Of the prior chemother-
apy, 9 subjects had prior paclitaxel, and 6 had prior
bevacizumab treatment. The only subject not treated with
prior paclitaxel had failed prior topotecan. The majority
of the subjects had prior pelvic radiation therapy (n = 9).
Subjects were treated with nab-paclitaxel with a dose
of 60 mg/m2 to 100 mg/m2. There were 5 dose reductions,
and 7 dose delays. Most common indication for treatment
alterations was myleosuppression. Eight subjects were
treated concomitantly with bevacizumab. A total of
65 cycles were completed; mean cycles completed 6.5
(range 2–19).
There were no grade 4 or 5 adverse events. The only
grade 3 adverse events were anemia-requiring transfusion
of packed red blood cells. One subject was diagnosed with
a vesicovaginal fistula during NAB-paclitaxel therapy. For a
complete list of adverse events please see Table 2.
Three subjects are still alive; one subject is currently re-
ceiving active treatment with NAB-paclitaxel. Median PFS
and OS for all subjects that met mortality endpoint were
4.8 and 8.9 months (n = 7), respectively (Figs. 1 and 2).
Median PFS and OS for the subjects treated with NAB-
paclitaxel and bevacizumab that meet mortality endpoint
was 6.9 and 14.02 months (n = 6), respectively. One subject
discontinued NAB-paclitaxel secondary to peripheral
neuropathy.
Discussion
NAB-paclitaxel has three Food and Drug Administration
(FDA) approved indications: locally advanced or meta-
static non-small cell lung cancer, metastatic adenocar-
cinoma of the pancreas, and metastatic breast cancer
after failure of combination chemotherapy or relapse
within 6 months of adjuvant therapy [12, 13]. There have
been limited evaluations of NAB-paclitaxel in cervical
cancer. Here we review our experience in treating heav-
ily pre-treated recurrent cervical cancer patients that
have failed prior cytotoxic chemotherapy.
NAB-paclitaxel was previously reviewed in the 127
series. This phase II study queue was launched in the
1990’s by the GOG to evaluate recurrent squamous cell
cervical cancer. Most agents studied were not effective
with overall response rates ranged from 0 to 22 %. In
this series, NAB-paclitaxel was the most effective agent
demonstrating a partial response in 10 of 35 subjects
(28.6 %). An additional 15 subjects experienced stable
disease (42.9 %) [14, 15].
In comparison, within the prior phase II evaluation of NAB-
paclitaxel in cervical cancer, our subjects were heavily pre-
treated, versus the paclitaxel naïve status of the prior study.
Table 2 Adverse Events










Nausea & Vomiting 5 0
Hypertension 1 0
Epistasis 1 0
Vesicovaginal Fistula 1 0
Pleural Effusion 2 0
Small Bowel Obstruction 1 0




























































Fig. 2 Overall survival. Median OS = 8.9 months (Range: 2.5-21.1 months)
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While that data supported further investigation of NAB-
paclitaxel, it is important to not disregard this significant limi-
tation. Furthermore, data here supports the metronomic ad-
ministration of this agent and this is the first report of such a
dosing schedule in the setting of recurrent cervical cancer.
One subject was diagnosed with a vesicovaginal fistula
during NAB-paclitaxel therapy. This subject was a 35 year
old initially diagnosed with stage IIA2 adenocarcinoma.
Nineteen months after her primary treatment of cisplatin
and radiation, she experienced her first recurrence, and was
treated with carboplatin and paclitaxel doublet therapy. Bi-
opsy proven recurrent disease was noted during surveillance.
The patient’s exam was notable for “thickened area palpable
inferior to the urethra”. This subject completed 11 cycles of
NAB-paclitaxel at 80 mg/m2 and bevacizumab 10 mg/kg,
and after eleventh cycle the fistula was detected on exam.
While this subject represents 10 % of our study popu-
lation, the authors argue that this is more likely a repre-
sentation of a pretreated-patient with extensive pelvic
disease. Furthermore, the occurrence of this complica-
tion is more likely due to the administered bevacizumab
with the known complication of fistula formation. This
is supported by the lack of fistulas that occurred in the
phase II study of NAB-paclitaxel. As this was a limited
study population, future studies will need to address the
incidence of fistulas during NAB-paclitaxel therapy.
While this study provides evidence for the feasibility
and tolerability of NAB-paclitaxel in the setting of recur-
rent cervical cancer, there are several limitations to this
data including: lack of patient reported outcomes, Re-
sponse Evaluation Criteria In Solid Tumors (RECIST)
response, and small study population.
Conclusions
In conclusion, anti-angiogenic therapy has proven pivotal in
the treatment of recurrent, metastatic and persistent cervical
cancer, however if a GOG-240 treatment regimen fails, there
are no established treatment options in recurrent cervical can-
cer.Metronomic-chemotherapymaybe another treatment op-
tion as this administration schedule produces anti-angiogenic
properties by effecting endothelial repair time, endothelial cell
proliferation, migration, and circulating levels of endothelial
progenitor cells. NAB-paclitaxel was overall well tolerated
with no grade 4 or 5 adverse events. NAB-paclitaxel with or
without bevacizumab is feasible and potentially active in treat-
ing recurrent cervical cancer after failing platinum-taxane or
topotecan chemotherapy. This small case series deserves con-
firmation through prospective clinical trials.
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